Lincoln Pharmaceuticals Ltd

Lincoln Pharmaceuticals Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by robust price action, positive signals from key technical indicators, and impressive returns that outpace the broader market benchmarks, signalling renewed investor interest in this micro-cap pharmaceutical player.

Lincoln Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 16 March 2026. While this rating change occurred in March, the analysis and financial metrics presented here reflect the stock's current position as of 13 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Lincoln Pharmaceuticals Ltd has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish trend as of mid-2026. While key indicators such as the MACD and Bollinger Bands maintain positive signals on weekly and monthly timeframes, divergences in RSI and KST readings suggest a complex outlook for investors navigating this micro-cap pharmaceutical stock.

Lincoln Pharmaceuticals Ltd has demonstrated a notable shift in price momentum, supported by a series of bullish technical indicators that have upgraded its outlook from a previous sell rating to a hold. With a current market price of ₹637.35, the micro-cap pharmaceutical stock is showing signs of renewed strength, outperforming the broader Sensex over multiple time horizons.

Lincoln Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 March 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 June 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Lincoln Pharmaceuticals Ltd has seen a notable shift in its valuation parameters, moving from a fair to an attractive rating, driven by improved price-to-earnings and price-to-book ratios relative to its historical averages and peer group. Despite a recent dip in share price, the company’s fundamentals and relative valuation metrics suggest a more compelling investment case within the Pharmaceuticals & Biotechnology sector.

Lincoln Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish trend as of early June 2026. Despite a significant day decline of 16.67%, the stock’s longer-term technical indicators present a complex picture, with bullish signals on weekly and monthly MACD and OBV, contrasted by bearish monthly RSI and KST readings. This nuanced technical landscape warrants a detailed analysis for investors seeking clarity on the stock’s near-term trajectory within the Pharmaceuticals & Biotechnology sector.

Lincoln Pharmaceuticals Ltd., the Ahmedabad-based pharmaceutical formulations manufacturer, reported a marginal 0.43% year-on-year increase in net profit to ₹11.63 crores for Q4 FY26, barely surpassing the ₹11.58 crores posted in Q4 FY25. The muted earnings growth came despite an 11.36% rise in net sales to ₹187.28 crores, as the company grappled with contracting operating margins and a significant negative swing in other income. The stock plummeted 10.73% on May 29, 2026, closing at ₹677.00, reflecting investor disappointment with the lacklustre quarterly performance from a company valued at ₹1,356 crores.

Surging to a fresh 52-week high of Rs 770 on 27 May 2026, Lincoln Pharmaceuticals Ltd has demonstrated robust price momentum, outperforming its sector and the broader market with a 37.3% gain over the past year against the Sensex’s decline of 6.9%.

With a decisive surge to an intraday high of Rs 749.45 on 26 May 2026, Lincoln Pharmaceuticals Ltd has nearly touched its 52-week peak, closing just 0.41% shy of the milestone. This rally has been underpinned by a confluence of bullish technical indicators and sustained price momentum, setting the stock apart in a market where the broader Sensex continues to struggle.

Lincoln Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 22 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

With a decisive breakthrough to Rs 745.1 on 22 May 2026, Lincoln Pharmaceuticals Ltd has reached a fresh 52-week high, extending its impressive 34.8% gain over the past year. This milestone comes amid a backdrop of strong technical momentum and sustained outperformance relative to the broader market indices.

With a decisive surge to Rs 732.45 on 21 May 2026, Lincoln Pharmaceuticals Ltd has reached a fresh 52-week high, marking a 66.4% rally from its low of Rs 439.95 over the past year. This milestone comes amid a backdrop of strong technical momentum, even as the broader market shows signs of volatility.

Lincoln Pharmaceuticals Ltd has witnessed a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish stance as of mid-May 2026. Despite a recent day decline of 2.83%, the stock’s technical indicators reveal a complex interplay of bullish and neutral signals, suggesting cautious optimism for investors amid mixed market conditions.

Lincoln Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 16 Mar 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.